Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Tuesday, July 29 2014 12:49pm ET - U.S. Markets close in 3 hours and 11 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > Esperion Therapeutics, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Esperion Therapeutics, Inc. Company Profile
"Bad" cholesterol is public enemy #1 at Esperion Therapeutics. A biopharmaceutical company, Esperion researches and develops therapies that reduce elevated LDL-C levels in patients' blood. Its primary candidate, ETC-1002, has been under development since 2008 and is in clinical stage development. If the candidate is approved by the FDA, the company plans to market its drug to patients who are unable to physically tolerate widely used cholesterol drugs like statins. Esperion Therapeutics was formed in 2008 after former parent Pfizer spun the company's predecessor off. Esperion went public in 2013.
Headlines for Esperion Therapeutics, Inc.
[$$] Preview
at Barrons.com - Sat Jul 26
[$$] Next Week
at Barrons.com - Sat Jul 26
ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online - Thu Jul 24
Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension
Business Wire - Thu Jul 24
More Headlines...
More on Esperion Therapeutics, Inc.
Quote Insider
News Financials
Profile    
Research    
Contact Information
Address: 46701 Commerce Center Dr.
Plymouth, MI 48170
Phone:734-862-4840
Fax:
Financial Highlights
Fiscal Year End:December
Revenue (2013):0.00 M
Employees (2013):17
Employee Growth (1 yr):30.80%
Key People
Executive Chairman, Chief Scientific Officer: Roger S. Newton
President, Chief Executive Officer and Director: Tim M. Mayleben
Vice President - Business Development: Troy Ignelzi
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
AstraZeneca Pharmaceuticals LP
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?